BioWorld

Dec. 15, 2005

View Archived Issues

Amgen Offers To Buy Out Abgenix For $2.2B In Cash

In what could become one of the top acquisitions of 2005, Amgen Inc. offered to acquire Abgenix Inc. for $22.50 a share - or about $2.2 billion in cash. (BioWorld Today) Read More

Zadaxin Phase III Miss Drops SciClone's Stock 40 Percent

Read More

Arena's Obesity Drug Yields Positive Results In Phase IIb

Read More

Optimer Brings In $34.2M To Advance Anti-Infectives

Read More

ActivBiotics, Metaphore Merge With Two Late-Stage Therapies

Read More

Human Genome Sciences Spinning Out CoGenesys

Read More

Other News To Note

Read More